Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus low-dose total nodal irradiation for chronic graft-versus-host disease
ACTRN12607000628448Phase 2Recruiting
- Sponsor
- Simon He and Andrew Grigg
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic graft-versus-host disease (cGVHD), sponsored by Simon He and Andrew Grigg. Primary endpoint: Safety and tolerability. Started Nov 2008; status: recruiting.
02
Drugs
rituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on ACTRN12607000628448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000628448.